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Abstract
Background: Fibronectin 1 (FN1) is a glycoprotein involved in cellular adhesion and migration processes. The aim
of this study was to elucidate the role of FN1 in development of renal cell cancer (RCC) and to determine a
prognostic relevance for optimal clinical management.
Methods: 212 renal tissue samples (109 RCC, 86 corresponding tissues from adjacent normal renal tissue and
17 oncocytomas) were collected from patients undergoing surgery for renal tumors and subjected to total RNA
extraction. Detection of FN1 mRNA expression was performed using quantitative real time PCR, three endogenous
controls, renal proximal tubular epithelial cells (RPTEC) as biological control and the ΔΔCt method for calculation of
relative quantities.
Results: Mean tissue specific FN1 mRNA expression was found to be increased approximately seven fold
comparing RCC and corresponding kidney control tissues (p < 0.001; ANOVA). Furthermore, tissue specific mean
FN1 expression was increased approx. 11 fold in clear cell compared to papillary RCC (p = 9×10
-5; Wilcoxon rank
sum test). Patients with advanced disease had higher FN1 expression when compared to organ-confined disease
(p < 0.001; Wilcoxon rank sum test). Applying subgroup analysis we found a significantly higher FN1 mRNA
expression between organ-confined and advanced disease in the papillary and not in the clear cell RCC group
(p = 0.02 vs. p = 0.2; Wilcoxon rank sum test). There was an increased expression in RCC compared to oncocytoma
(p = 0.016; ANOVA).
Conclusions: To our knowledge, this is the first study to show that FN1 mRNA expression is higher in RCC
compared to normal renal tissue. FN1 mRNA expression might serve as a marker for RCC aggressiveness, indicating
early systemic progression particularly for patients with papillary RCC.
Background
Renal cell carcinoma (RCC) is a common urologic tumor
and accounts for about 3% of all human malignancies [1].
The annual mortality-to-incidence ratio of RCC is signifi-
cantly higher compared to other urological malignancies,
and its incidence has been increasing steadily in recent
decades [2]. Interestingly, even organ-confined RCC of
comparable stage and grade can demonstrate a signifi-
cantly-varying tendency towards tumor progression and
systemic spread. Correspondingly, the development of
metastases can be observed in a substantial number of
patients with tumors initially classified as stage T1b or
T2 even more than five years after the initial treatment,
hereby demonstrating the limited value of classical
patients’ and tumor characteristics such as tumor stage
and grade to predict the clinical outcome of an individual
patient.
An essential step in local disease progression and in
the formation of metastases is the invasion of tumour
cells into the extracellular matrix. Cell adhesion mole-
cules and extra-cellular matrix proteins support either
an increase or a decrease in the ability of tumours cells
to adhere to surrounding tissue. Among the extracellular
matrix proteins identified, Fibronectin (FN) seems to
play an important role in both inhibition and promotion
of cellular attachment by interacting with different
receptors.
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sion and migration processes including embryogenesis,
wound healing, blood coagulation, host defense, and
metastasis. The molecule is widely distributed in healthy
membrane, in the lamina propria, in vessel structures,
nerves and smooth-muscle cell layers [3]. However, up
to now the function of FN is not clearly known [4,5].
Few studies described the potential role of FN in differ-
ent malignancies [5-8]. For example in hepatocellular
carcinoma an overexpression of FN protein was found
[7]. Elevated plasma levels were detected in patients suf-
fering from gastrointestinal and head/neck cancer [5]. In
non-malignant diseases particularly in thrombosis,
hemostasis, vascular disease and platelet function the
definitive role of FN is still unclear [9-11].
T h ea i mo ft h i ss t u d yi st oe l u c i d a t eap o s s i b l er o l eo f
FN1 in the development of RCC using mRNA expression
analyses. 212 renal tissue samples from patients under-
going surgery for renal tumors were analysed using quan-
titative real time PCR. FN1 mRNA expression was
significantly increased in RCC compared to corresponding
normal renal tissue. Furthermore, our data suggest FN1 as
marker for progressive disease especially in papillary RCC.
Methods
Tissue specimens
Tumors and corresponding tumour free tissue of 126
patients subjected to kidney surgery between 2001 and
2005 collected from the Eberhard Karls University Tue-
bingen were included in the present investigation. All
tumors were freshly obtained from the urological depart-
ment’s operation room. The ethical committee of the
institution approved the study. Two pathologists evalu-
ated all specimens with respect to tumor stage, grade and
histological subtypes. Tumor stages were assessed
according to the UICC 2002 issue of the TNM system
[12] and nuclear grading was based on the Fuhrman
grading system [13]. Histological subtypes were assessed
according to the consensus classification of renal cell
neoplasia [14] Organ-confined RCC was defined as pT ≤
2 and N0/M0 and advanced as pT≥3a n d / o rN + / M + .
The resected tissues were stored at -80°C. Data were
collected by physicians and data managers and subse-
quently maintained by a relational database. Clinical and
histopathological data are summarized in table 1.
Primary cells
Renal proximal tubular epithelial cells (RPTEC) were
obtained from Lonza (Basel, Switzerland) and cultured
according to the manufactures recommendations.
Quantitative real-time PCR analysis
Total RNA was isolated from 20 cyro sections (each
20 μm) using TriReagent (Ambion) according to the
manufacturers’ instructions. Furthermore, of each tissue
sample two sections were stained with hematoxylin-eosin
and evaluated by a pathologist (J.U.B). Total RNA was
reverse-transcribed into single-strand complementary
DNA (cDNA) using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA,
USA). Quantitative real time PCR analyses were
performed in duplicate with an ABI 7900 Fast Sequence
Detection System using TaqMan gene expression
assays and universal PCR master mix according to the
Table 1 Clinical and histopathological data of patients
with renal cell cancer
Clinico-pathological parameters Number of
patients
%
Total 109 100
Age (mean; ± SD) 63 ± 11.9
male 70 64.2
female 39 35.8
Side
left 49 45
right 60 55
Surgery
PN 27 24.8
RN 82 75.2
Histology
clear cell 78 71.6
papillary 22 20.2
chromophobe 2 1.8
other/not classified 7 6.4
Stage
pT1a 34 31.2
pT1b 30 27.5
pT2 5 4.6
pT3a 13 11.9
pT3b/c 27 24.8
pT4 0 0
LN metastasis
1 11 10.1
Pulmonal/visceral
metastasis
1
23 21.1
Advanced/metastatic disease (pT3-4 and/or
N/M+)
48 44.0
Grade
G1 18 16.5
G1-2 15 13.8
G2 58 53.2
G2-3 7 6.4
G3 11 10.1
1 at time of renal surgery;
Abbreviations: SD = standard deviation, PN = partial nephrectomy, RN =
radical nephrectomy, LN = lymph node.
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Page 2 of 6manufacturer’s specifications (Applied Biosystems). The
TaqMan assays were FN1 (Assay ID: Hs00365058_m1),
GUSB (Hs00939627_m1), RPL13A (Hs03043885_g1) and
HPRT1 (Hs99999909_m1). The human GUSB, RPL13A
and HPRT1 transcripts served as endogenous controls;
cDNA derived from RPTEC primary cell transcripts served
as biological control. Additional no-template, no reverse
transcription and blank controls were included in each run.
Data were evaluated using the SDS 2.3 Manager,
dataAssist V1.0 software and the ΔΔCt method [15,16].
The three endogenous controls were combined using
the dataAssist software V1.0 and “arithmetic mean” as
normalization method. The method of Livak et al [16]
and reference ΔCt values obtained from the biological
control RPTEC were applied for calculation of ΔΔCt
and relative quantity values, respectively. All statistics
were done using the R-package 2.10.0 and Java Gui for
R 1.7-0. For visual comparison of univariate data we
used bean plots as a combination of one-dimensional
scatter plots and density plots were generated using the
bean plot package for R statistical software [17]. In all
tests, p < 0.05 was considered to indicate significance.
Results
FN1 mRNA expression in normal renal tissues, RCC and
oncocytomas
In order to examine the mRNA expression of FN1 in RCC,
109 tumour RNA samples and corresponding histopatho-
logical normal renal tissue of 86 of these patients were
analysed using quantitative real time PCR. Furthermore,
17 tissue samples of oncocytomas were examined. Expres-
sion of FN1 was observed in all analysed samples. Mean
tissue specific FN1 mRNA expression was found to be
increased approximately seven fold comparing RCC and
corresponding kidney control tissues (p < 0.001; ANOVA).
There was no significant difference in FN1 expression
between normal renal tissue and oncocytoma. However,
there was an increased expression in RCC compared to
oncocytoma (p = 0.016; ANOVA; figure 1, table 2).
Clinical observations
We investigated if any correlations of interest could be
seen between the expression of FN1 and clinical para-
meters (table 1). The mean age of the cohort was 63
years (SD ± 11.9). Seventy patients were men (64.2%)
and 39 patients were women (35.8%). Seventy-eight
patients presented with clear cell RCC, 22 patients with
papillary RCCs, and two patients with chromophobe
RCC and seven patients with unclassified histology.
We found a significant difference in FN1 mRNA
expression between clear cell RCC and papillary RCC.
T h et i s s u es p e c i f i cm e a nFN1 expression was increased
approx. 11 fold in clear cell RCC compared to papillary
RCC (p = 9 ×10
-5;W i l c o x o nr a n ks u mt e s t ;f i g u r e2 ) .
No significant correlation was observed for histological
grading, TNM group stage, lymph node metastasis and
the presence of distant metastases (Spearman R non-
parametric correlation analysis).
Furthermore, we compared FN1 mRNA expression
between patients with organ-confined RCC (pT ≤ 2a n d
N0/M0) and advanced disease (pT≥3a n d / o rN + / M + ) .
Both, organ-confined and advanced disease showed sig-
nificantly higher levels of FN1 mRNA expression com-
pared to normal renal tissues (p = 0.022 and p < 1×10
-7
respectively; ANOVA; figure 3). Patients with advanced
disease had higher FN1 expression when compared to
organ-confined disease (p < 0.001; Wilcoxon rank sum
test; figure 3). We then divided the cohort in two
groups, clear cell RCC and papillary RCC. Interestingly,
Figure 1 Bean plot analysis of relative FN1 mRNA expression in
normal renal tissue, oncocytoma and RCC. Bean plots represent
an alternative to boxplots. The individual observations are shown as
small lines in a one-dimensional scatter plot, the estimated density
of the distributions is visible and the average is shown. Mean tissue
specific FN1 mRNA expression was increased approx. 7 fold in RCC
compared to corresponding normal renal tissue (p < 0.001) and
oncocytoma (p = 0.016). There was no significant difference in FN1
expression between normal renal tissue and oncocytoma.
Abbreviations: FN1RQ = Relative quantity of FN1 mRNA expression
analysis using RPTEC primary cells as a biological calibrator; normal =
normal renal tissue; Oncocyt = oncocytoma.
Table 2 FN1 mRNA expression in normal renal tissue,
RCC and oncocytoma
Tissue Number of tissues FN1RQ
Normal 86 0.0118
RCC 109 0.0821
Oncocytoma 17 0.0117
Total 212
Abbreviations: FN1RQ = Relative quantity of FN1 mRNA expression.
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cantly higher FN1 mRNA expression between organ-
confined and advanced disease in the papillary RCC and
not in the clear cell RCC group (p = 0.02 vs. p = 0.2;
Wilcoxon rank sum test, figures 4 and 5).
Discussion
FN1 mRNA expression and its relationship to clinico-
pathological parameters in RCC has not yet been inves-
tigated. Functional studies have shown that FN and its
receptors are important in mediating cell adhesion,
migration, signal transduction and possibly in preven-
tion of apoptosis [18]. It is a component of the extracel-
lular matrix, and cells adhere to FN via the integrin
transmembrane receptors. Either up-regulation or
down-regulation [19-21] of FN has been reported in sev-
eral human cancers. The ability to promote epithelial
cell migration and suppression of apoptosis, suggest that
FN overexpression promote various tumors types
[22,23].
In the present study, a significantly increased expres-
sion of FN1 mRNA in RCC compared to normal renal
tissue and oncocytoma has been shown. Both organ-
confined (pT ≤ 2 and N0/M0) and advanced disease
(pT≥3 and/or N+/M+) showed significant higher levels
of FN1 mRNA expression compared to normal renal tis-
sue. Moreover, patients with advanced disease had
higher FN1 expression when compared to organ-con-
fined disease. This supports the hypothesis that FN con-
tributes to renal carcinogenesis and/or RCC progression.
There have been previous functional studies suggest-
ing FN as a candidate marker for aggressive RCC. The
first studies focusing on different RCC cell lines showed
altered FN secretion and the possibility to influence
mobility and invasiveness of these malignant cells
[24-26].
Figure 2 FN1 mRNA expression in clear cell RCC and papillary
RCC. Mean tissue specific FN1 expression was increased approx. 11
fold in clear cell RCC compared to papillary RCC (p < 0.001).
Abbreviations: FN1RQ = Relative quantity of FN1 mRNA expression
analysis using RPTEC primary cells as a biological calibrator; ccRCC =
clear cell RCC; pRCC = papillary RCC.
Figure 3 Bean plot analysis of stage specific Expression: FN1
mRNA expression in organ-confined (pT ≤ 2 and N0/M0) and
advanced RCC (pT≥3 and/or N+/M+), with a higher FN1
expression in advanced disease (p < 0.001). Abbreviations:
FN1RQ = Relative quantity of FN1 mRNA expression analysis using
RPTEC primary cells as a biological calibrator; normal = normal renal
tissue; local = organ-confined RCC; advanced = advanced RCC.
Figure 4 Progression specific Expression in papillary RCC:
higher FN1 mRNA in advanced (pT≥3 and/or N+/M+)
compared to organ-confined (pT ≤ 2 and N0/M0) RCC (p =
0.017). Abbreviations: FN1RQ = Relative quantity of FN1 mRNA
expression analysis using RPTEC primary cells as a biological calibrator;
local = organ-confined RCC; advanced = advanced RCC.
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icant increase in FN1 mRNA expression in clear cell
RCC compared to papillary RCC. Our results generally
suggest that an increased FN1 expression is correlated
to a more progressive disease in RCC. Moreover, higher
FN1 expression in clear cell RCC as compared to papil-
lary RCC support the common belief that papillary
tumors are less aggressive [27]. On the other hand cur-
rent data indicates that once papillary RCC has spread,
it is associated with a poor survival and a higher risk of
resistance to systemic therapy compared to clear cell
RCC [28]. This statement is supported by the fact that
we found a significant higher FN1 mRNA expression
between organ-confined and advanced disease in papil-
lary RCC but not for clear cell RCC. Papillary RCC can
be sub classified into types 1 and 2 as well as into less
and more aggressive tumors. FN1 m i g h tb eu s e dt od i f -
ferentiate between papillary RCC with less or more
aggressive potential.
Conclusion
To our knowledge, this is the first study to show that
FN1 mRNA expression is significantly higher in RCC
compared to normal renal tissue and oncocytoma. FN1
mRNA expression might serve as a marker for RCC
aggressiveness, indicating early systemic progression par-
ticularly for patients with papillary RCC. Therefore, our
data on FN1 encourages further investigations to
enlighten the future role of FN1 in RCC.
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